600998.SHG Jointown Pharmaceutical Group Co Ltd
- Market cap
- CNY 26.9B
- P/E
- 14.1x
- P/B
- 0.97x
- ROE
- 7.7%
- Dividend yield
- 5.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600998.SHG undervalued?
Graham number600998.SHG trades 22.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jointown Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Jointown Pharmaceutical Group Co Ltd yet.
Jointown Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jointown Pharmaceutical Group Co Ltd
Jointown Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the digital pharmaceutical distribution and supply chain business in China. It operates through Distribution, Industrial, Retail, Medical and Health, and Other divisions. The company offers distribution, warehousing, medical and pharmaceutical logistics, and other services to pharmaceutical manufacturers; medicines and health products; medical, health, and technology value-added services; and …
Full company profileJointown Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jointown Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 61.6B | 73.9B | 87.1B | 99.5B | 111B | 122B | 140B | 150B | 152B | 161B | 173B |
| Gross Profit | 4.80B | 6.21B | 7.49B | 8.67B | 9.88B | 9.77B | 10.9B | 12.0B | 11.7B | 12.5B | 13.9B |
| Operating Income | 1.05B | 1.94B | 1.83B | 2.30B | 4.35B | 3.59B | 2.85B | 3.02B | 3.64B | 4.04B | 4.52B |
| EBITDA | 1.98B | 2.42B | 2.94B | 3.72B | 4.24B | 3.63B | 4.42B | 4.73B | 4.61B | 5.14B | 4.20B |
| Net Income | 877M | 1.45B | 1.34B | 1.73B | 3.08B | 2.45B | 2.08B | 2.17B | 2.51B | 2.25B | 2.24B |
| EPS | 0.20 | 0.32 | 0.27 | 0.31 | 0.58 | 0.47 | 0.40 | 0.43 | 0.50 | 0.45 | 0.44 |
| Balance Sheet | |||||||||||
| Total Assets | 38.7B | 52.0B | 66.7B | 71.1B | 80.8B | 85.9B | 92.3B | 92.8B | 102B | 116B | 124B |
| Total Liabilities | 26.7B | 32.5B | 46.3B | 49.2B | 55.2B | 58.9B | 63.6B | 63.3B | 68.8B | 79.5B | 85.8B |
| Shareholders' Equity | 11.3B | 18.3B | 18.5B | 18.8B | 21.8B | 23.4B | 24.6B | 24.0B | 27.2B | 28.6B | 29.3B |
| Cash & Short-term Investments | 5.24B | 8.54B | 12.7B | 12.2B | 14.8B | 18.3B | 17.5B | 17.0B | 18.4B | 18.8B | 22.0B |
| Total Debt | 6.82B | 8.50B | 11.9B | 14.6B | 17.7B | 17.0B | 15.2B | 12.6B | 11.7B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 431M | -1.01B | 1.22B | 2.77B | 3.44B | 3.46B | 3.99B | 4.78B | 3.08B | 3.44B | - |
| Capital Expenditure | 1.15B | 1.09B | 1.81B | 1.19B | 1.46B | 1.39B | 1.24B | 1.05B | 975M | 1.40B | 1.24B |
| Free Cash Flow | -719M | -2.10B | -593M | 1.58B | 1.99B | 2.07B | 2.74B | 3.70B | 2.11B | 2.04B | -3.93B |
| Ratios | |||||||||||
| ROE | 7.8% | 7.9% | 7.3% | 9.2% | 14.1% | 10.5% | 8.5% | 9.1% | 9.2% | 7.9% | 7.7% |
| ROA | 2.3% | 2.8% | 2.0% | 2.4% | 3.8% | 2.8% | 2.3% | 2.3% | 2.4% | 1.9% | 1.8% |
| Net Profit Margin | 1.4% | 2.0% | 1.5% | 1.7% | 2.8% | 2.0% | 1.5% | 1.4% | 1.7% | 1.4% | 1.3% |
| Debt to Equity | 0.60x | 0.46x | 0.64x | 0.78x | 0.81x | 0.73x | 0.62x | 0.53x | 0.43x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jointown Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 5.49%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 65.6%
- Ex-dividend date
- Jun 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.48B | 0.29 | 65.6% |
| 2024 | CNY 1.55B | 0.31 | 62.0% |
| 2023 | CNY 937M | 0.19 | 43.1% |
| 2022 | CNY 549M | 0.10 | 26.3% |
| 2021 | CNY 914M | 0.18 | 37.3% |
| 2020 | CNY 738M | 0.14 | 24.0% |
| 2019 | CNY 187M | 0.03 | 10.9% |
| 2018 | CNY 967M | 0.19 | 72.1% |
| 2017 | CNY 709M | 0.16 | 49.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.29:1 on Jun 7, 2024.
Who owns Jointown Pharmaceutical Group Co Ltd
- Insiders 56.98%
- Institutions 12.84%
- Public & others 30.18%
- Shares outstanding 5.04B
- Free float 1.97B
Jointown Pharmaceutical Group Co Ltd company profile
- Company name
- Jointown Pharmaceutical Group Co Ltd
- Ticker
- 600998.SHG
- ISIN
- CNE100000W45
- Exchange
- Shanghai Stock Exchange
- Listed since
- Nov 2, 2010
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 29,862
- Fiscal year end
- December
- Address
- No. 5, Longxing West Street, Wuhan, China, 430051
- Phone
- 86 27 8468 3017
- Website
- jointown.com
About Jointown Pharmaceutical Group Co Ltd
Jointown Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the digital pharmaceutical distribution and supply chain business in China. It operates through Distribution, Industrial, Retail, Medical and Health, and Other divisions. The company offers distribution, warehousing, medical and pharmaceutical logistics, and other services to pharmaceutical manufacturers; medicines and health products; medical, health, and technology value-added services; and digital logistics technology and supply chain solutions. It is also involved in the operation and franchising of retail pharmacy networks; general agency brand promotion business; pharmaceutical OEM business; and wholesale of medical devices. Jointown Pharmaceutical Group Co., Ltd was founded in 1999 and is headquartered in Wuhan, China.
Jointown Pharmaceutical Group Co Ltd management
10- Mr. Yihua GongGM & Vice Chairman · born 1978
- Mr. Yi Chang LiuBusiness President & Vice Chairman · born 1975
- Mr. Xiao Yi XiaAccounting Supervisor & Financial Director · born 1978
- Ms. Ju Mei YangDeputy General Manager · born 1975
- Ms. Lei GuoDeputy General Manager · born 1978
- Mr. Wei HeVP & Director · born 1986
- Mr. Xiling SuDeputy GM, VP, COO of REITs · born 1991
- Mr. Liu ZhifengDeputy GM & Secretary of the Board of Directors · born 1983
- Mr. Qi Bing WangDeputy General Manager · born 1965
- Ms. Ming QuanDeputy General Manager · born 1989